他指出他的公司之所以勇于向新生市场发起冲击，是因为非专利药品和运用生物科技的药品是等效的，也为了证明像他一样的公司不是一无所能的。
He points to his firm’s aggressive entry into the nascent market for “biosimilars”, which are the generic equivalents of biotechnology drugs, as proof that firms like his need not be toothless.
他指出他的公司之所以勇于向新生市场发起冲击，是因为非专利药品和运用生物科技的药品是等效的，也为了证明像他一样的公司不是一无所能的。
He points to his firm’s aggressive entry into the nascent market for “biosimilars”, which are the generic equivalents of biotechnology drugs, as proof that firms like his need not be toothless.
应用推荐